Expression and mutational analysis of the MADR2/smad2 gene in human prostate cancer

Prostate

Volumn 40, Issue 4, 1999, Pages 225-231

  Latil, Alain ^a   Pesche, Sandrine ^a   Valéri, Antoine ^b   Fournier, Georges ^b   Cussenot, Olivier ^c   Lidereau, Rosette ^a  

^a CENTRE RENÉ HUGUENIN   (France)

^b SERVICE DE RHUMATOLOGIE   (France)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

MADR2 smad2 gene; Prostate cancer; Quantitative reverse transcription polymerase chain reaction; Single strand conformational polymorphism; Tumor suppressor gene

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CARCINOGENESIS; CHROMOSOME 18Q; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; GENE; GENE EXPRESSION; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

BIOPSY, NEEDLE; CHROMOSOMES, HUMAN, PAIR 18; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; DNA, COMPLEMENTARY; DNA-BINDING PROTEINS; ELECTROPHORESIS, AGAR GEL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; MALE; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SEQUENCE ANALYSIS, DNA; SMAD2 PROTEIN; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0032769147     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990901)40:4<225::AID-PROS3>3.0.CO;2-3     Document Type: Article

References (39)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI, Isaacs WB. Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA 1990;87:8751-8755.
3. Bova GS, Carter BS, Bussemakers MJG, Emi M, Fujiwara Y, Kiprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC, Isaacs WB. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 1993;53:3869-3873.
4. Latil A, Baron J-C, Cussenot O, Fournier G, Soussi T, Boccon-Gibod L, Leduc A, Rouesse J, Lidereau R. Genetic alterations in localized prostate cancer: identification of a common region of deletion on chromosome 18q. Genes Chromosomes Cancer 1994;11:119-125.
5. Zenklusen JC, Thompson JC, Troncoso P, Kagan J, Conti CJ. Loss of heterozygosity in human primary prostate carcinomas: a possible tumor suppressor gene at 7q31.1. Cancer Res 1994; 54:6370-6373.
6. Gao X, Zacharek A, Salkowski A, Grignon DJ, Sakr W, Porter AT, Honn KV. Loss of heterozygosity of BRCA1 and other loci on chromosome 17q in human prostate cancer. Cancer Res 1995; 55:1002-1005.
7. Cooney KA, Wetzel JC, Merajver SD, Macoska JA, Singleton TP, Wojno KJ. Distinct regions of allelic loss on 13q in prostate cancer. Cancer Res 1996;56:1142-1145.
8. Ittmann M. Allelic loss on chromosome 10 in prostate adenocarcinoma. Cancer Res 1996;6:2143-2147.
9. Crundwell MC, Chughtai S, Knowles M, Takle L, Luscombe M, Neoptolemos JP, Morton DG, Phillips SMA. Allelic loss on chromosomes 8p, 22q, and 18q (DCC) in human prostate cancer. Int J Cancer 1996;69:295-300.
10. Cunningham JM, Shan A, Wick MJ, McDonnell SK, Schaid DJ, Tester DJ, Qian J, Takahashi S, Jenkins RB, Bostwick DG, Thibodeau SN. Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res 1996;56:4475-4482.
11. Ueda T, Komiya A, Emi M, Suzuki H, Shiraishi T, Yatani R, Masai M, Yasuda K, Ito H. Allelic losses on 18q21 are associated with progression and metastasis in human prostate cancer. Genes Chromosomes Cancer 1997;20:140-147.
12. Jenkins R, Takahashi S, DeLacey K, Bergstralh E, Lieber M. Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3N0M0 prostate cancer. Genes Chromosomes Cancer 1998;21:131-143.
13. Gao X, Honn KV, Grignon D, Sakr W, Chen YQ. Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinomas. Cancer Res 1993; 53:2723-2727.
14. Hahn SA, Schutte M, Hoque ATMS, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-353.
15. Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, Tsui L-C, Bapat B, Gallinger S, Andrulis IL, Thomsen GH, Wrana JL, Attisano L. MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996;86:543-552.
16. Riggins GJ, Thiagalingam S, Rozenblum E, Weinstein CL, Kern SE, Hamilton SR, Willson JKV, Markowitz SD, Kinzler KW, Vogelstein B. Mad-related genes in the human. Nat Genet 1996;13: 347-349.
17. Alexandrow MG, Moses HL. Transforming growth factor β and cell cycle regulation. Cancer Res 1995;55:1452-1457.
18. Thiagalingam S, Lengauer C, Leach FS, Schutte M, Hahn SA, Overhauser J, Willson JKV, Markowitz S, Hamilton SR, Kern SE, Kinzler KW, Vogelstein B. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996;13:343-346.
19. Hahn SA, Bartsch D, Schroers A, Galehdari H, Becker M, Ramaswamy A, Schwarte-Waldhoff I, Maschek H, Schmiegel W. Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. Cancer Res 1998;58:1124-1126.
20. Kim SK, Fan Y, Papadimitrakopoulou V, dayman G, Hittelman WN, Hong WK, Lotan R, Mao L. DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. Cancer Res 1996; 56:2519-2521.
21. Nagatake M, Takagi Y, Osada H, Uchida K, Mitsudomi T, Saji S, Shimokata K, Takahashi T, Takahashi T. Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res 1996;56:2718-2720.
22. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, Bova GS, Isaacs WB, Cairns P, Nawroz H, Sidransky D, Casero RA Jr, Meltzer PS, Hahn SA, Kern SE. DPC4 gene in various tumor types. Cancer Res 1996;56:2527-2530.
23. MacGrogan D, Pegram M, Slamon D, Bookstein R. Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas. Oncogene 1997;15:1111-1114.
24. Uchida K, Nagatake M, Osada H, Yatabe Y, Kondo M, Mitsudomi T, Masuda A, Takahashi T, Takahashi T. Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers. Cancer Res 1996;56:5583-5585.
25. Mellinger GT, Gleason D, Bailar J III. The histology and prognosis of prostatic cancer. J Urol 1967;97:331-337.
26. Schroder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate [Suppl] 1992;4:129-138.
27. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
28. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990;215:403-410.
29. Takenoshita S, Mogi A, Nagashima M, Yang K, Yagi K, Hanyu A, Nagamachi Y, Miyazono K, Hagiwara K. Characterization of the MADH2/Smad2 gene, a human Mad homolog responsible for the transforming growth factor-β and activin signal transduction pathway. Genomics 1998;48:1-11.
30. Lazar V, Gil Diez SG, Laurent A, Giovangrandi Y, Radvanyi F, Chopin D, Bidart J-M, Bellet D, Vidaud M. Expression of human chorionic gonadotropin β subunit genes in superficial and invasive bladder carcinomas. Cancer Res 1995;55:3735-3738.
31. Foley KP, Leonard MW, Engel JD. Quantitation of RNA using the polymerase chain reaction. Trends Genet 1993;9:380-385.
32. Lagna G, Hata A, Hemmati-Brivanlou A, Massagué J. Partnership between DPC4 and SMAD protein in TGF-β signalling pathways. Nature 1996;383:832-836.
33. Hata A, Lo RS, Wotton D, Lagna G, Massagué J. Mutations increasing autoinhibition inactivate tumor suppressors Smad2 and Smad4. Nature 1997;388:82-87.
34. Kretzschmar M, Liu F, Hata A, Doody J, Massagué J. The TGF-β family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase. Genes Dev 1997; 11:984-995.
35. Kong X-T, Choi SH, Inoue A, Xu F, Chen T, Takita J, Yokota J, Bessho F, Yanagisawa M, Hanada R, Yamamoto K, Hayashi Y. Expression and mutational analysis of the DCC, DPC4, and MADR2/JV18-1 genes in neuroblastoma. Cancer Res 1997;57: 3772-3778.
36. Maesawa C, Tamura G, Nishizuka S, Iwaya T, Ogasawara S, Ishida K, Sakata K, Sato N, Ikeda K, Kimura Y, Saito K, Satodate R. MAD-related genes on 18q21.1, Smad2 and Smad4, are altered infrequently in esophageal squamous cell carcinoma. Jpn J Cancer Res 1997;88:340-343.
37. Shi Y, Hata A, Lo RS, Massagué J, Pavletich NP. Structural basis for mutational inactivation of the tumor suppressor Smad4. Nature 1997;388:87-93.
38. Cavanee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL, Murphee AL, Strong LC, White RL. Expression of the recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 1983;305:779-784.
39. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AMM, Bos JL. Genetic alterations during colorectal tumor development. N Engl J Med 1988;319:213-221.